• SBIJI Innovation

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease

- BX002 demonstrated safety and tolerability with successful delivery of a high concentration of viable phage to the lower gastrointestinal tract -

- First clinical study detailing pharmacokinetics of oral phage therapy under a U.S. FDA IND protocol -

- Efficacy results in reduction of target bacteria expected by mid-2022 from planned Phase 1b/2a study -

Read More


Recent Posts

See All

Chemomab Completes Merger with Anchiano Therapeutics

Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB" Combined company will focus on advancing Chemomab's CM-101 current

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved